The position of long-term stimulation of the endogenous fibrinolytic system: present achievements and clinical perspectives.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D045930:Anabolic Agents / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000378:metabolism; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D010629:Phenformin / Q000627:therapeutic use; D010960:Plasminogen Activators; D011183:Postoperative Complications / Q000517:prevention & control; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013923:Thromboembolism / Q000378:metabolism; D013924:Thrombophlebitis / Q000517:prevention & control; D014652:Vascular Diseases / Q000378:metabolism
D045930:Anabolic Agents; D000728:Androgens; D005343:Fibrinolytic Agents; D005938:Glucocorticoids; D013453:Sulfonylurea Compounds; D000324:Adrenocorticotropic Hormone; D008687:Metformin; D010629:Phenformin; D010960:Plasminogen Activators; D003894:Deamino Arginine Vasopressin; D002994:Clofibrate